{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:37:19Z","timestamp":1793317039300,"version":"4.5.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.phrs.2022.106359","type":"journal-article","created":{"date-parts":[[2022,7,27]],"date-time":"2022-07-27T01:58:10Z","timestamp":1658887090000},"page":"106359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted"],"prefix":"10.1016","volume":"183","author":[{"given":"Maurizio","family":"Benucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Damiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Infantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Lari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Li","family":"Gobbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piercarlo","family":"Sarzi-Puttini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2022.106359_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.phrs.2022.106359_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2022.106359_bib3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41584-021-00593-3","article-title":"Cardiovascular effects of approved drugs for rheumatoid arthritis","volume":"17","author":"Atzeni","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106359_bib4","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/art.30134","article-title":"The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan","volume":"63","author":"Chen","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.phrs.2022.106359_bib5","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/rheumatology\/ken130","article-title":"Cancer risk in hospitalized rheumatoid arthritis patients","volume":"47","author":"Hemminki","year":"2008","journal-title":"Rheuma Oxf. Engl."},{"issue":"6","key":"10.1016\/j.phrs.2022.106359_bib6","first-page":"1001","article-title":"Risk of cancer among rheumatoid arthritis patients in California","volume":"20","author":"Parikh-Patel","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"9","key":"10.1016\/j.phrs.2022.106359_bib7","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/1756-185X.13655","article-title":"Incidence and patterns of malignancies in a multi-ethnic cohort of rheumatoid arthritis patients","volume":"22","author":"Lim","year":"2019","journal-title":"Int J. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.phrs.2022.106359_bib8","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.phrs.2022.106359_bib9","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/annrheumdis-2014-207155","article-title":"What is the impact of chronic systemic infammation such as rheumatoid arthritis on mortality following cancer?","volume":"75","author":"Simard","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.phrs.2022.106359_bib10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nri1703","article-title":"NF-kappaB: linking infammation and immunity to cancer development and progression","volume":"5","author":"Karin","year":"2005","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106359_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/1541-7786.MCR-05-0261","article-title":"Infammation, a key event in cancer development","volume":"4","author":"Lu","year":"2006","journal-title":"Mol. Cancer Res. MCR"},{"issue":"3","key":"10.1016\/j.phrs.2022.106359_bib12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic infammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2022.106359_bib13","doi-asserted-by":"crossref","unstructured":"Ytterberg S.R., Bhatt D.L., Mikuls T.R., Koch G.G., Fleischmann R., Rivas J.L., Germino R., Menon S., Sun Y., Wang C., Shapiro A.B., Kanik K.S., Connell C.A.; ORAL Surveillance Investigators. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.N Engl J Med. 2022 Jan 27;386(4):316\u2013326.","DOI":"10.1056\/NEJMoa2109927"},{"key":"10.1016\/j.phrs.2022.106359_bib14","unstructured":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions Up-date 12-2021."},{"key":"10.1016\/j.phrs.2022.106359_bib15","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/rheumatology\/keaa374","article-title":"Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population","volume":"60","author":"Logstrup","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2022.106359_bib16","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1136\/annrheumdis-2013-204531","article-title":"The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients","volume":"74","author":"Arts","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2022.106359_bib17","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1136\/annrheumdis-2014-207178","article-title":"Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs","volume":"75","author":"Charles-Schoeman","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2022.106359_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semarthrit.2016.05.014","article-title":"Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor","volume":"46","author":"Charles-Schoeman","year":"2016","journal-title":"Semin Arthritis Rheum."},{"key":"10.1016\/j.phrs.2022.106359_bib19","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","article-title":"Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomized controlled trials","volume":"78","author":"Xie","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2022.106359_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development program","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.phrs.2022.106359_bib21","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/art.40911","article-title":"Risk factors for major adverse cardiovascular events in phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis","volume":"71","author":"Charles-Schoeman","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2022.106359_bib22","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40744-018-0097-3","article-title":"Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis","volume":"5","author":"Cohen","year":"2018","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.phrs.2022.106359_bib23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/acr2.11232","article-title":"Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry","volume":"3","author":"Kremer","year":"2021","journal-title":"ACR Open Rheumatol."},{"key":"10.1016\/j.phrs.2022.106359_bib24","unstructured":"Pfizer shares co-primary endpoint results from post-marketing required safety study of XELJANZ\u00ae (tofacitinib) in subjects with rheumatoid arthritis (RA). [cited 2022 Feb 3]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-co-primary-endpoint-results-post-marketing."},{"key":"10.1016\/j.phrs.2022.106359_bib25","unstructured":"Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC). 2021 Jun 7\u201310.https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessmentcommittee-prac-7\u201310-june-2021."},{"key":"10.1016\/j.phrs.2022.106359_bib26","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheuma"},{"key":"10.1016\/j.phrs.2022.106359_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106359_bib28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","article-title":"Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database","volume":"81","author":"Taylor","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2022.106359_bib29","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","volume":"80","author":"Cohen","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2022.106359_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40264-020-01036-w","article-title":"Upadacitinib in rheumatoid arthritis: a benefit-risk assessment across a phase III program","volume":"44","author":"Conaghan","year":"2021","journal-title":"Drug Saf."},{"key":"10.1016\/j.phrs.2022.106359_bib31","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or Abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106359_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002012","article-title":"Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study","volume":"8","author":"Fleischmann","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.phrs.2022.106359_bib33","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2022.106359_bib34","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or Adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomized clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"10.1016\/j.phrs.2022.106359_bib35","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3899\/jrheum.201183","article-title":"Safety and efficacy of filgotinib: up to 4-year results from an open-label extension studt of phase II rheumatoid arthritis programs","volume":"48","author":"Kavanaugh","year":"2021","journal-title":"J. Rheuma"},{"issue":"2","key":"10.1016\/j.phrs.2022.106359_bib36","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/annrheumdis-2021-221051","article-title":"Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years","volume":"81","author":"Winthrop","year":"2022","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2022.106359_bib37","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208105","article-title":"How comparable are rates of malignancies in patients with rheumatoid arthritis across the world? A comparison of cancer rates, and means to optimise their comparability, in five RA registries","volume":"75","author":"Askling","year":"2016","journal-title":"Ann. Rheum. Dis."},{"issue":"5164","key":"10.1016\/j.phrs.2022.106359_bib38","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","article-title":"Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins","volume":"264","author":"Darnell","year":"1994","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.phrs.2022.106359_bib39","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.3390\/cancers11122002","article-title":"JAK-STAT signaling: a doubleedged sword of immune regulation and cancer progression","volume":"11","author":"Owen","year":"2019","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.phrs.2022.106359_bib40","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1002\/jcp.29593","article-title":"Janus kinase inhibitors: a therapeutic strategy for cancer and autoimmune diseases","volume":"235","author":"Hosseini","year":"2020","journal-title":"J. Cell Physiol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106359_bib41","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.semarthrit.2020.08.007","article-title":"Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies","volume":"50","author":"Xie","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"#cr-split#-10.1016\/j.phrs.2022.106359_othref0025.1","doi-asserted-by":"crossref","unstructured":"(a) Solipuram V., Mohan A., Patel R., Ni R.Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.Auto Immun Highlights. 2021 Apr 28;12(1):8. (b) Maneiro J.R., Souto A., Gomez-Reino J.J., editors. Risksof malignancies related to tofacitinib and biologicaldrugs in rheumatoid arthritis: systematic review,meta-analysis, and network meta-analysis. Seminars in arthritis and rheumatism. Amsterdam: Elsevier","DOI":"10.1186\/s13317-021-00153-5"},{"key":"#cr-split#-10.1016\/j.phrs.2022.106359_othref0025.2","doi-asserted-by":"crossref","unstructured":"(a) Solipuram V., Mohan A., Patel R., Ni R.Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.Auto Immun Highlights. 2021 Apr 28;12(1):8.","DOI":"10.1186\/s13317-021-00153-5"},{"key":"#cr-split#-10.1016\/j.phrs.2022.106359_othref0025.3","doi-asserted-by":"crossref","unstructured":"(b) Maneiro J.R., Souto A., Gomez-Reino J.J., editors. Risksof malignancies related to tofacitinib and biologicaldrugs in rheumatoid arthritis: systematic review,meta-analysis, and network meta-analysis. Seminars in arthritis and rheumatism. Amsterdam: Elsevier; 2017.","DOI":"10.1016\/j.semarthrit.2017.02.007"},{"key":"#cr-split#-10.1016\/j.phrs.2022.106359_othref0030.1","doi-asserted-by":"crossref","unstructured":"(a) Solipuram V., Mohan A., Patel R., Ni R.Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.Auto Immun Highlights. 2021 Apr 28;12(1):8. (b) Maneiro J.R., Souto A., Gomez-Reino J.J., editors. Risksof malignancies related to tofacitinib and biologicaldrugs in rheumatoid arthritis: systematic review,meta-analysis, and network meta-analysis. Seminars in arthritis and rheumatism. Amsterdam: Elsevier","DOI":"10.1186\/s13317-021-00153-5"},{"key":"#cr-split#-10.1016\/j.phrs.2022.106359_othref0030.2","doi-asserted-by":"crossref","unstructured":"(a) Solipuram V., Mohan A., Patel R., Ni R.Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.Auto Immun Highlights. 2021 Apr 28;12(1):8.","DOI":"10.1186\/s13317-021-00153-5"},{"key":"#cr-split#-10.1016\/j.phrs.2022.106359_othref0030.3","doi-asserted-by":"crossref","unstructured":"(b) Maneiro J.R., Souto A., Gomez-Reino J.J., editors. Risksof malignancies related to tofacitinib and biologicaldrugs in rheumatoid arthritis: systematic review,meta-analysis, and network meta-analysis. Seminars in arthritis and rheumatism. Amsterdam: Elsevier; 2017.","DOI":"10.1016\/j.semarthrit.2017.02.007"},{"key":"10.1016\/j.phrs.2022.106359_sbref38","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an oral Janus kinase inhibitor:analysis of malignancies across the rheumatoid arthritis clinical development programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2022.106359_sbref39","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/acr.23421","article-title":"Lymphoma in the tofacitinib rheumatoid arthritisclinical development program","volume":"70","author":"Mariette","year":"2018","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.phrs.2022.106359_bib44","first-page":"2874","article-title":"Comparison of malignancy and mortality rates between tofacitinib and biologicDMARDs in clinical practice: five-year results from a US-based rheumatoid arthritis registry","volume":"71","author":"Kremer","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2022.106359_bib45","first-page":"1515","article-title":"Malignancy in Japanese patients with rheumatoid arthritis treated with tofacitinib: interim analysis of all-case post-marketing surveillance","volume":"70","author":"Tamura","year":"2018","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106359_bib46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822003048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822003048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:35:24Z","timestamp":1760913324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822003048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":52,"alternative-id":["S1043661822003048"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106359","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106359"}}